- Home
- SRL vs CLYM Comparison
SRL vs CLYM Comparison
Compare SRL & CLYM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SRL
- CLYM
- Stock Information
- Founded
- SRL 2017
- CLYM 2018
- Country
- SRL China
- CLYM United States
- Employees
- SRL N/A
- CLYM N/A
- Industry
- SRL Professional Services
- CLYM
- Sector
- SRL Consumer Discretionary
- CLYM
- Exchange
- SRL Nasdaq
- CLYM NYSE
- Market Cap
- SRL 89.5M
- CLYM 83.8M
- IPO Year
- SRL N/A
- CLYM 2021
- Fundamental
- Price
- SRL $5.98
- CLYM $1.37
- Analyst Decision
- SRL
- CLYM Buy
- Analyst Count
- SRL 0
- CLYM 1
- Target Price
- SRL N/A
- CLYM $10.00
- AVG Volume (30 Days)
- SRL 5.0K
- CLYM 389.6K
- Earning Date
- SRL 07-22-2025
- CLYM 08-13-2025
- Dividend Yield
- SRL 17.13%
- CLYM N/A
- EPS Growth
- SRL N/A
- CLYM N/A
- EPS
- SRL N/A
- CLYM N/A
- Revenue
- SRL $24,535,042.00
- CLYM N/A
- Revenue This Year
- SRL N/A
- CLYM N/A
- Revenue Next Year
- SRL N/A
- CLYM N/A
- P/E Ratio
- SRL N/A
- CLYM N/A
- Revenue Growth
- SRL N/A
- CLYM N/A
- 52 Week Low
- SRL $5.70
- CLYM $1.05
- 52 Week High
- SRL $9.99
- CLYM $9.21
- Technical
- Relative Strength Index (RSI)
- SRL 44.71
- CLYM N/A
- Support Level
- SRL $5.84
- CLYM N/A
- Resistance Level
- SRL $6.42
- CLYM N/A
- Average True Range (ATR)
- SRL 0.24
- CLYM 0.00
- MACD
- SRL 0.06
- CLYM 0.00
- Stochastic Oscillator
- SRL 55.56
- CLYM 0.00
About SRL Scully Royalty Ltd.
Scully Royalty Ltd is a royalty-based company that maximizes earnings upon its iron ore royalty interest. The company's business segments include Royalty, which includes an interest in an iron ore mine; Industrial, which includes projects in resources and services; Merchant Banking, which comprises regulated merchant banking activities; and others. The majority of the revenue is generated from the Royalty segment. The company's geographical segments include Canada, Africa, America, Asia, and Europe, out of which Canada accounts for the majority of the revenue.
About CLYM CLIMB BIO INC
Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. its product candidate, budoprutug, is an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has the potential to treat a broad range of B-cell-mediated diseases.